Dow Down3.39% Nasdaq Down4.12%

More On 009420.KS



News & Info


Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates


  • Major Holders
  • Insider Transactions
  • Insider Roster


HanAll Biopharma Co., Ltd. (009420.KS)

19,600.00 Down 1,800.00(8.41%) Jun 24, 2:00AM EDT
ProfileGet Profile for:
HanAll Biopharma Co., Ltd.
I-Space Building
6th Floor
Seoul, 138-922
South Korea - Map
Phone: 82 2 2204 1753
Fax: 82 2 414 1951

Index Membership:N/A
Full Time Employees:N/A

Business Summary 

HanAll BioPharma Co., Ltd. engages in the research and development of biopharmaceutical products worldwide. Its products under development include HL161, an anti-hFcRn mAb for the treatment of pemphigus, NMO, MG, and lupus nephritis, as well as to treat autoimmune diseases caused by IgG auto antibodies and immune complex mediated glomerular diseases; and HL036, a TNF-alpha receptor fragment for the treatment of inflammatory diseases caused by TNF-alpha, such as uveitis, dry eyes, and AMD. The company also develops HL040, a combination of atorvastatin and losartan for the treatment of hyperlipidemia and hypertension; HL063B, a combination of telmisartan and chlorathalidone for hypertension; HL068, a combination of amlodipine and candesartan for the treatment of hypertension; HL009, an adenosylcobalamin liposomal gel for atopic dermatisis; HL018, a metformin acetate for obesity/DM2; HL143, a Hanferon for the prevention of postoperative HCC recurrence; and HL032, an oral Vitatropin for growth hormone deficiency, as well as HL172, a metformin HCl. HanAll BioPharma Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on HanAll Biopharma Co., Ltd.

Key Executives 
Han-Soo Lee , 52
Exec. Director of Fin. and Director
Mr. Seung-Kook Park Ph.D., M.B.A., 53
Head of Research, Exec. VP and Director
Mr. Seong-Jin Kim , 55
Exec. Director of HR and Director
Sung-Soo Jeon , 79
Jae-Hwan Kim , 67
Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in KRW.